CagriSema is likely to reach market sooner, but retatrutide offers the greatest peak efficacy of any single anti-obesity agent
Future directions in inflammatory bowel disease management
Insurers may view weight-loss drugs as a compelling preventive measure due to the high cost of treating these illnesses
The most common side effects include: Nausea and vomiting (especially in the first few weeks) Diarrhea or constipation Headache Fatigue Loss of appetite These side effects usually go away as the body adapts, but it is important to start with a low dose and gradually increase it
The primary outcome was the occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke
Published case reports of GLP-1-associated anaphylaxis confirm that cross-reactivity between different GLP-1 agents can occur, meaning a person allergic to exenatide might also react to lixisenatide but tolerate liraglutide or semaglutide, which have different molecular structures